Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25422970 | 0.89 | LPL (0.37) | LPLLIPGJAK2BTKTNF | |
| SCHEMBL30484203 | 0.87 | LPL (0.33) | LPLLIPG | |
| SCHEMBL24595249 | 0.87 | LPL (0.33) | LPLLIPG | |
| SCHEMBL2317559 | 0.83 | CFB (0.33) | LPLLIPGJAK2BTK | |
| SCHEMBL20577340 | 0.82 | LPL (0.34) | LPLLIPGJAK2BTK | |
| SCHEMBL30892219 | 0.81 | AHR (0.33) | LPLLIPGJAK2BTK | |
| SCHEMBL15186916 | 0.81 | AHR (0.33) | LPLLIPGJAK2BTK | |
| SCHEMBL20577313 | 0.81 | JAK2 (0.37) | LPLLIPGJAK2BTK | |
| SCHEMBL15186950 | 0.81 | KDM4E (0.43) | LPLLIPG | |
| SCHEMBL20576307 | 0.80 | EGFR (0.34) | LPLLIPGJAK2BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | disclosed |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | GRUENENTHAL GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-05-14 | — | — | US | disclosed |
| EP-3823970-B1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-03 | — | — | EP | disclosed |
| CN-111954525-B | Prodrugs of fused bicyclic C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023116594-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海安诺达生物科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-9133180-B2 | Aurora and FLT3 kinases modulators | SAREUM LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133180-B2 | Aurora and FLT3 kinases modulators | SAREUM LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9045496-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| EP-2678342-B1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-20140309219-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2014-10-16 | — | — | US | disclosed |
| US-8791107-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2678342-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2014-01-01 | — | — | EP | disclosed |
| WO-2013117522-A1 | AURORA AND FLT3 KINASES MODULATORS | SAREUM LIMITED (GB) | 2013-08-15 | — | — | WO | disclosed |
| WO-2012148548-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-01 | — | — | WO | disclosed |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309219-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | LPL 1567/4885LIPG 753/4885JAK2 25/4885 |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | LPL 1567/4885LIPG 753/4885JAK2 25/4885 |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | LPL 2148/4885LIPG 912/4885JAK2 1230/4885 |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | NR3C1, GRK5, NR3C2 | LPL 4179/4885LIPG 2444/4885JAK2 2124/4885 |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | LPL 4179/4885LIPG 2444/4885JAK2 2124/4885 |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | NR3C1, NR3C2, GRK5 | LPL 4415/4885LIPG 2751/4885JAK2 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.